Journey Medical Corporation Reports Strong Q3 2025 Growth
Journey Medical Corporation reported strong Q3 2025 growth with net revenues of $17.6 million, a 21% increase from the previous year. Emrosi™ drove growth with a 146% rise in prescriptions, generating $4.9 million in sales. Gross margin was 67.4%, and net loss improved to $2.3 million. Adjusted EBITDA rose to $1.7 million. Cash reserves increased to $24.9 million. The company is optimistic about Emrosi's continued growth and its strategic initiatives in the dermatology market.
Fortress Biotech Inc ( (FBIO) ) has released its Q3 earnings. Here is a breakdown of the information Fortress Biotech Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Journey Medical Corporation is a commercial-stage pharmaceutical company that specializes in selling and marketing FDA-approved prescription products for dermatological conditions. Based in Scottsdale, Arizona, the company is known for its efficient sales and marketing model and its portfolio of eight branded prescription drugs.
In the third quarter of 2025, Journey Medical Corporation reported net revenues of $17.6 million, marking a 21% increase from the previous year. The company’s growth was significantly driven by its product Emrosi™, which saw a 146% increase in total prescriptions and generated $4.9 million in net sales. The company also highlighted the clinical differentiation of Emrosi, which was validated through a Phase 3 efficacy analysis.
Key financial metrics for the quarter included a gross margin of 67.4%, slightly lower than the previous year’s 69.4% due to one-time non-operational adjustments in 2024. Selling, general, and administrative expenses rose by 6% to $12.1 million, primarily due to the launch and commercialization of Emrosi. The company reported a net loss of $2.3 million, an improvement from the $2.4 million loss in the same quarter of the previous year. Notably, Adjusted EBITDA improved to $1.7 million from $0.3 million in the prior year.
Journey Medical’s recent corporate highlights include expanded payer access for Emrosi, now covering over 100 million commercial lives in the U.S., and the presentation of efficacy data at a major dermatology conference. The company’s cash and cash equivalents increased to $24.9 million as of September 30, 2025, up from $20.3 million at the end of 2024.
Looking ahead, Journey Medical’s management remains optimistic about the continued growth of Emrosi and its established dermatology commercial infrastructure, which they believe will generate significant operating leverage. The company is poised to strengthen its position in the dermatology market with its innovative products and strategic initiatives.
